Investors had been waiting like cats at a fishmonger's for news on Bristol-Myers Squibb's test of its two breakthrough cancer drugs, Yervoy and Opdivo, in lung cancer. PD-L1 positive patients would receive one of three treatments: the combination of Opdivo and Yervoy, Opdivo alone, or chemotherapy. PD-L1 negative patients would receive the combination of Opdivo and Yervoy, Opdivo plus chemo, or chemo alone. Investors expected to find out whether the Opdivo and Yervoy beat chemo or Opdivo alone. The company had already increased the size of the study – there were now 1200 PD-L1 positive patients, and 700 PD-L1 negative ones – and pooled the results.

Source: Forbes February 05, 2018 23:03 UTC